The Food and Drug Administration on Thursday announced the approval of Ruconest, a recombinant C1-Esterase inhibitor product for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema.
Drug maker Shire is extending the deadline for its offer to buy Exton, Pa.-based ViroPharma for $4.2 billion, Shire said Friday.
Drug maker ViroPharma has launched an education campaign focused on a rare, debilitating and life-threatening genetic disorder.
The Food and Drug Administration has approved a drug made by Shire for a rare autoimmune condition, the agency said.
British drug maker Shire again is trying to win approval for a hereditary angioedema drug that the Food and Drug Administration had previously declined to approve.